A tiny, wire-free implant positioned behind the retina has given some reading back to people living on the brink of irreversible blindness caused by macular degeneration. The international clinical trial led by Stanford Medicine showed a result that is difficult to ignore, of 32 patients, 27 returned to reading after a year of use.

The publication in the New England Journal of Medicine marked the point at which Prima stopped being just research and began to indicate a real path of visual rehabilitation, the operation is direct, almost elegant, macular degeneration destroys photoreceptors, cells that transform light into electrical impulses.

Prima occupies exactly that lost space, with just 2 mm, the chip receives infrared light sent by a microcamera attached to special lenses, there, hundreds of microelectrodes convert the signal into stimuli that reach the brain as recognizable patterns, no cables, no internal batteries. The light itself powers the system, reducing risks and keeping the implant stable under the retina.

Training begins weeks after surgery and initial results follow a consistent rhythm, shapes, enlarged letters, contours, after a year, most distinguish signs and read text with contrast optimized by the lenses. The reported side effects such as small subretinal hemorrhages and temporary increase in eye pressure draw attention precisely because they are controllable.

The prosthesis replaces our natural vision, introducing a technically precise alternative route that allows us to recover functions previously considered permanently lost. The Science Corporation, responsible for the commercial adaptation, foresees the arrival of the Prima on the European market in 2026; The new generation of the chip expands the field of view and increases resolution, bringing the experience closer to face recognition and finer details.

They are incremental but structural advances that consolidate the prosthesis not only as a solution for macular degeneration, but as a platform for future biohybrid neural interfaces. When diseases such as Parkinson's and the consequences of ACB enter the same technological discussion, the question stops being about the chip itself and becomes about what an artificial retina represents.

Science seems to insist that the reconstruction of the body can come from silicon and infrared light, perhaps the limit between seeing and not seeing has never been biological, but technical.